Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies

illustrate how rapidly the field is evolving, but also how heterogeneous the underlying biology, clinical development strategies and toxicity profiles remain.Several contributions focus on acute leukemia, where bispecific T cell engagers were first clinically established. Cao et al. summarize the most recent bispecific antibody data presented at the 66th American Society of Hematology meeting, encompassing both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia, as well as combinations with chemotherapy and other targeted agents. Their conference-based overview highlights not only consistently high measurable residual disease (MRD) negativity rates in relapsed/refractory B-ALL but also the diversification of targets and platforms entering clinical testing, as well as the operational challenges of delivering these agents outside highly specialized centers. This Research Topic shows bispecific and other multispecific antibodies that move from hematologic malignancies into lung and other solid tumors, including heavily pretreated, high-risk patients. They enable MRD-focused strategies, options for such disease and precision use guided by immunophenotype and genetics, but at the price of immune toxicities, serious infections and infusions that require close monitoring (4,5). Translational work on cytokine-fusion, trispecific and other advanced formats shows how they remodel the tumor microenvironment, mobilize effector cells and counter immune escape and other resistance. Meta-analyses, real-world cohorts and smaller clinical series define priorities: biomarker-based target selection, integration with cellular therapies and radiation therapy, and long-term safety, sequencing, and survivorship study.Built to bridge diseases and disciplines, this 2024-2025 snapshot spans diverse cancers and study stages and aims to inform the next generation of bispecific and multispecific therapies.